Minimal Residual Disease (MRD)

The persistence of cancerous cells after treatment, known as minimal (or measurable) residual disease, may lead to relapse.

Even after remission, small traces of malignant cells that remain can lead to relapse, limited treatment options, and poor patient outcomes^1-3
Evolving science and knowledge of MRD as a prognostic indicator is shaping treatment choice and overall patient management^4,5
As part of our ongoing commitment to improving patient outcomes, Amgen continues to explore innovative approaches for eradicating MRD across multiple hematologic malignancies. Amgen is leading the way in MRD+ B-cell precursor ALL and is committed to advancing the science to fulfill our mission of serving patients.

Detecting MRD: Methods and Sensitivity^6,7

Diagnostic test

Sensitivity

Flow cytometryA rapid and qualitative method of identifying cancer cells

1 cancer cell in 10,000 normal cells

Polymerase chain reactionA well-established method in which a specific section of DNA from cancer cells is replicated and amplified

1 cancer cell in 100,000 normal cells

Next-generation sequencingAn extremely sensitive DNA sequencing method

1 cancer cell in 1,000,000 normal cells

Where is your nearest MRD testing facility?

The link below is an informational resource to help healthcare providers locate MRD testing facilities for clinically appropriate patients. Amgen does not refer, recommend, or endorse healthcare providers or facilities listed here. The selection of a healthcare provider is a patient's choice and should be carefully considered. Please contact facilities directly to learn more about the availability of MRD testing at these locations.

DOWNLOAD THE LIST

Minimum Residual Disease (MRD) research leads to new discoveries in treating cancers

Learn about MRD and the potential risk for relapse with this interactive game.

PLAY THE GAME

Booklet cover of Minimal Residual Disease in Hematologic Malignancies

Download the brochure that focuses on MRD in hematologic malignancies and looks at the tools used to detect these residual cells.

DOWNLOAD THE BOOKLET

Slide deck cover of Minimal Residual Disease Testing in Hematoloic Malignancies

Download the MRD slide deck to learn about:

Response evaluation in hematologic malignancies
Technical aspects of MRD measurement
Incorporation of MRD results into patient management

DOWNLOAD THE SLIDE DECK

References: 1. Jain N, et al. In: Hoffman R, et al, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Saunders-Elsevier; 2013:960-980. 2. Gökbuget N, et al. Blood. 2012;120:1868-1876. 3. Pettit K, et al. Leuk Lymphoma. 2016;57:1527-1533. 4. Berry DA, et al. JAMA Oncol. 2017;3:e170580. 5. Harousseau J-L, et al. J Clin Oncol. 2017;35:2863-2865. 6. Campana D. Semin Hematol. 2009;46:100-106. 7. Ladetto M, et al. Leukemia. 2014;28:1299-1307.

DISEASE STATE EDUCATION

Minimal Residual Disease (MRD)

The persistence of cancerous cells after treatment, known as minimal (or measurable) residual disease, may lead to relapse.

Detecting MRD: Methods and Sensitivity^6,7

Where is your nearest MRD testing facility?

MRD in acute lymphoblastic leukemia

For more information on MRD, play our interactive game and download the resources below

DISEASE STATE EDUCATION

Minimal Residual Disease (MRD)

The persistence of cancerous cells after treatment, known as minimal (or measurable) residual disease, may lead to relapse.

Detecting MRD: Methods and Sensitivity6,7

Where is your nearest MRD testing facility?

MRD in acute lymphoblastic leukemia

For more information on MRD, play our interactive game and download the resources below

Detecting MRD: Methods and Sensitivity^6,7